Dogwood Therapeutics, Inc. Operating Cash Flow
Dogwood Therapeutics, Inc. (DWTX) reported Operating Cash Flow of -$8.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.61M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.59M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.64M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.27M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$15.62M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$8.79M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$4.87M.
- Dogwood Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$11.47M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.20M 10-Q · filed 2026-08-14 | -$11.84M derived: sum of 3 quarters · filed 2026-08-14 | -$15.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$4.59M 10-Q · filed 2026-05-15 | -$8.22M derived: sum of 2 quarters · filed 2026-05-15 | -$11.50M derived: sum of 3 quarters · filed 2026-05-15 | -$15.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$6.91M derived: sum of 2 quarters · filed 2026-03-18 | -$10.94M derived: sum of 3 quarters · filed 2026-08-14 | -$15.62M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$3.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$7.30M derived: sum of 2 quarters · filed 2026-08-14 | -$11.98M 10-Q · filed 2025-11-07 | -$18.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$4.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.71M 10-Q · filed 2026-08-14 | -$14.84M derived: sum of 3 quarters · filed 2026-08-14 | -$15.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$4.68M 10-Q · filed 2026-05-15 | -$10.81M derived: sum of 2 quarters · filed 2026-05-15 | -$11.72M derived: sum of 3 quarters · filed 2026-05-15 | -$12.54M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$7.04M derived: sum of 2 quarters · filed 2026-03-18 | -$7.85M derived: sum of 3 quarters · filed 2026-03-18 | -$8.79M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$910.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.72M derived: sum of 2 quarters · filed 2025-11-07 | -$2.66M 10-Q · filed 2025-11-07 | -$4.13M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$811.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.75M 10-Q · filed 2025-08-13 | -$3.22M derived: sum of 3 quarters · filed 2025-08-13 | -$4.18M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$937.41K 10-Q · filed 2025-05-09 | -$2.41M derived: sum of 2 quarters · filed 2025-05-09 | -$3.37M derived: sum of 3 quarters · filed 2025-05-09 | -$4.11M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$2.43M derived: sum of 2 quarters · filed 2025-03-31 | -$3.17M derived: sum of 3 quarters · filed 2025-03-31 | -$4.87M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$960.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$1.70M derived: sum of 2 quarters · filed 2024-11-08 | -$3.40M 10-Q · filed 2024-11-08 | -$6.07M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$742.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$2.44M 10-Q · filed 2024-08-09 | -$5.11M derived: sum of 3 quarters · filed 2024-08-09 | -$7.60M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$1.70M 10-Q · filed 2024-05-10 | -$4.37M derived: sum of 2 quarters · filed 2024-05-10 | -$6.85M derived: sum of 3 quarters · filed 2024-05-10 | -$10.51M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$2.67M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | -$5.15M derived: sum of 2 quarters · filed 2024-03-08 | -$8.81M derived: sum of 3 quarters · filed 2024-03-08 | -$11.47M 10-K/A · filed 2024-03-08 |
| 2022-09-30 | -$2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$6.14M derived: sum of 2 quarters · filed 2023-11-13 | -$8.80M 10-Q · filed 2023-11-13 | -$13.97M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$6.31M 10-Q · filed 2023-08-11 | -$11.49M derived: sum of 3 quarters · filed 2023-08-11 | -$14.14M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$2.66M 10-Q · filed 2023-05-12 | -$7.83M derived: sum of 2 quarters · filed 2023-05-12 | -$10.48M derived: sum of 3 quarters · filed 2023-05-12 | -$13.23M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$7.83M derived: sum of 2 quarters · filed 2023-03-14 | -$10.58M derived: sum of 3 quarters · filed 2023-03-14 | -$15.69M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$5.40M derived: sum of 2 quarters · filed 2022-11-14 | -$10.51M 10-Q · filed 2022-11-14 | -$12.80M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$7.86M 10-Q · filed 2022-08-12 | -$10.15M derived: sum of 3 quarters · filed 2022-08-12 | -$10.71M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$5.11M 10-Q · filed 2022-05-13 | -$7.40M derived: sum of 2 quarters · filed 2022-05-13 | -$7.96M derived: sum of 3 quarters · filed 2022-05-13 | -$8.73M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$2.85M derived: sum of 2 quarters · filed 2022-03-18 | -$3.62M derived: sum of 3 quarters · filed 2022-03-18 | -$3.90M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$558.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.33M derived: sum of 2 quarters · filed 2021-11-12 | -$1.61M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$772.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$1.05M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$277.38K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |